Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan

Cancer Chemother Pharmacol. 1990;25(6):449-53. doi: 10.1007/BF00686058.

Abstract

A total of 33 patients with myeloma receiving treatment with high-dose melphalan (140-200 mg/m2 i.v.) were given the 5HT3 antagonist Ondansetron (Glaxo) as an antiemetic. In 42% of patients, emetic episodes were either abolished (15%) or reduced to two or less (27%). Efficacy was not related to scheduling (two regimens) or total dose. No sedative or other significant side effects were seen. Ondansetron is a highly effective non-sedative antiemetic that justifies further assessment in combination with other antiemetics in patients receiving cytotoxic drugs associated with the production of severe nausea and vomiting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Antiemetics / administration & dosage
  • Antiemetics / pharmacokinetics
  • Antiemetics / therapeutic use*
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / pharmacokinetics
  • Imidazoles / therapeutic use*
  • Infusions, Intravenous
  • Male
  • Melphalan / administration & dosage
  • Melphalan / adverse effects*
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / drug therapy*
  • Nausea / chemically induced
  • Nausea / prevention & control*
  • Ondansetron
  • Serotonin Antagonists
  • Vomiting / chemically induced
  • Vomiting / prevention & control*

Substances

  • Antiemetics
  • Imidazoles
  • Serotonin Antagonists
  • Ondansetron
  • Melphalan